YS Biopharma Granted Phase I Clinical Trial License Of Therapeutic Chronic Hepatitis B Virus Vaccine
YS Biopharma Granted Phase I Clinical Trial License Of Therapeutic Chronic Hepatitis B Virus Vaccine
YS Biopharma获得治疗性慢性乙型肝炎病毒疫苗的I期临床试验许可
YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that its YS-HBV-002 immunotherapeutic vaccine, designed to treat patients suffering from chronic hepatitis B virus ("HBV") infection, has been granted clinical trial approval by the Philippine Food and Drug Administration ("PFDA"). In light of the approval, the Company is preparing to initiate a Phase I clinical trial for YS-HBV-002 in the Philippines, which is expected to begin in June 2024.
YS Biopharma Co., Ltd.（纳斯达克股票代码：YS）（“YS Biopharma” 或 “公司”）是一家致力于发现、开发、制造和交付用于传染病和癌症的新一代疫苗和治疗生物制剂的全球生物制药公司，今天宣布，其设计用于治疗慢性乙型肝炎病毒（“HBV”）感染患者的 YS-HBV-002 免疫治疗疫苗具有已获得菲律宾食品药品监督管理局（“PFDA”）的临床试验批准。鉴于获得批准，该公司正准备在菲律宾启动 YS-HBV-002 的 I 期临床试验，该试验预计于 2024 年 6 月开始。
Chronic HBV infection...
慢性乙...
登录免费看全文
登录/注册